Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02499952 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors
A Phase 2 study, sponsored by Nasser Hanna, M.D..
- Terminated
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT02499952 is a Phase 2 study that was terminated before completion, run by Nasser Hanna, M.D.. The registered enrollment target is 12 participants.
The verdict
NCT02499952, a Phase 2 study, was terminated before completion, sponsored by Nasser Hanna, M.D..
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
This is an open label, multi-institutional, single arm phase II trial of pembrolizumab in patients with incurable platinum refractory germ cell tumors. No randomization or blinding is involved.
Interventions
- DRUG Pembrolizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2016-01 |
| Est. Completion | 2017-01-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02499952
The ClinicalTrials.gov registry entry for NCT02499952 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nasser Hanna, M.D., which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pembrolizumab is the first listed.
NCT02499952 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02499952 about?
NCT02499952 is a clinical study titled "Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors". This is an open label, multi-institutional, single arm phase II trial of pembrolizumab in patients with incurable platinum refractory germ cell tumors. No randomization or blinding is involved.
What is the current status of trial NCT02499952?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2016-01. Estimated completion is 2017-01-13.
What interventions are being tested in trial NCT02499952?
The interventions under investigation include: Pembrolizumab (DRUG).
Who is sponsoring clinical trial NCT02499952?
This trial is sponsored by Nasser Hanna, M.D., which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.